USPTO serial 79433974
NORDICCTX-III
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 13, 2026
- Examiner
- SEVERSON, JUSTIN
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with NORDICCTX-III?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Bradley M. Stohry
Bradley M. Stohry Reichel Stohry Dean LLP6151 Central AveIndianapolis, IN 46220United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic biomarker reagents for medical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; diagnostic biomarker assays to identify disease activity for medical use; diagnostic biomarker assays for medical use to quantify disease activity; diagnostic biomarker assays for medical use to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for testing bodily fluids for use in disease detection, disease analysis and quantifying disease activity; diagnostic agents for medical use; diagnostic reagents for medical use; clinical diagnostic agents; clinical diagnostic reagents for medical use; diagnostic preparations, diagnostic substances and diagnostic materials for medical purposes; medical diagnostic test strips for testing samples for the presence of biomarkers; diagnostic preparations for medical purposes | ACTIVE | — |
| 042 | Design and development of blood-based biomarker assays for the identification, quantification and analysis of disease activity; design and development of diagnostic biomarker reagents for medical purposes, for pharmaceutical purposes and for scientific purposes; design and development of biochemical and pharmaceutical assays and medical assays; design and development of biomarkers for individual use or combined for the tracking of tissue formation, development or tissue degradation; pharmaceutical and scientific research in the fields of biomarkers and the detection of biomarkers; medical research, namely, identification of predictive and prognostic biomarkers for clinical trials; medical research, namely, identifying patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to clinical trials; scientific research in the nature of conducting clinical trials for others; medical research, namely, analysis of pharmacodynamic data; medical research, namely, analysis of data relating to biomarkers; development of diagnostic preparations for medical purposes, diagnostic equipment and diagnostic tests; medical research laboratory services relating to clinical testing services for others; providing reagent sample testing and diagnostic services for others for scientific research purposes; medical research services, namely, testing services relating to the tracking and measurement of biomarkers; medical research services, namely, testing samples for the presence of biomarkers; scientific laboratory services; medical research laboratory services; medical research laboratories; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research services involving experimentation, development, and analysis | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Nordic Bioscience A/S
- Other trademarks owned by Nordic Bioscience A/S
- Other trademarks owned by Nordic Bioscience A/S
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named NORDICCTX-III
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 13, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Oct 13, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 24, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 27, 2026 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Aug 25, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 25, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 19, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 5, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 5, 2026 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jul 27, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 17, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 17, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 17, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 19, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 3, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 3, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 8, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 7, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 29, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 5, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 5, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 2, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |